Eli Lilly & Co (LLY)
AI stock analysis · as of May 26, 2026
Loading microstructure…
Eli Lilly is a large-cap pharma whose narrative has been transformed into a tirzepatide (Mounjaro/Zepbound) growth story, with 2025 revenue of ~$65B (up ~45% YoY) and net margins expanding to ~32%. The core investment question is whether Lilly can sustain hyper-growth by scaling manufacturing, defending share against Novo Nordisk and oral GLP-1 entrants, and converting its pipeline (retatrutide, Verve, Kisunla) into the next leg — all while justifying a ~38x P/E and ~$950B market cap.
This analysis is from May 26, 2026. Want the latest on LLY, plus the ability to generate fresh research on demand?
Every call we make is tracked publicly against what the stock actually did. See the track record →
One free AI report every day. No card required.
Bull case
- · Explosive top-line growth: revenue grew from $34.1B (2023) to $65.2B (2025), a near-doubling in two years, with net income tripling from $5.2B to $20.6B — operating leverage is real.
- · Tirzepatide franchise has multiple expansion vectors: obesity, T2D, obstructive sleep apnea approval, and international rollout where penetration is nascent.
- · Retatrutide phase data reportedly showing bariatric-surgery-level weight loss positions Lilly to leapfrog its own franchise and stay ahead of Novo's semaglutide.
- · Gross margins ~83% and expanding, reflecting pricing power and mix shift to high-margin biologics; FCF will inflect once capex cycle peaks.
- · Pipeline optionality from M&A (Verve gene editing for CV, Scorpion oncology, Morphic, Point Biopharma) plus Kisunla in early Alzheimer's diversifies beyond GLP-1.
- · Sell-side consensus buy rating with 29 analysts and $1,211 mean target implies ~14% upside; sentiment score 0.62 reflects constructive newsflow.
Bear case
- · Valuation is stretched: 37.9x P/E and ~$950B cap leave little room for disappointment; news flow already flags 'too late to buy' concerns after a 7x five-year run.
- · Revenue concentration risk — tirzepatide is the overwhelming growth driver, and Trulicity is already being cannibalized; any tirzepatide setback (supply, safety, competition) would be severe.
- · Free cash flow of only $5.96B against $20.6B net income reflects massive capex on manufacturing build-out; if demand normalizes before capacity comes online, returns on invested capital suffer.
- · Balance sheet leverage rising: $42.5B total debt vs. only $7.3B cash, with new tranches issued in 2025 to fund acquisitions — financial flexibility narrowing.
- · Competitive wall closing in: Novo's semaglutide franchise, oral GLP-1s, and Chinese biosimilar entrants threaten pricing and share within 2-4 years.
- · Policy overhang: IRA negotiation, voluntary pricing agreements, and employer opt-in dynamics for obesity coverage cap U.S. realized pricing; tariff risk on Ireland-heavy manufacturing footprint.
Catalysts
- · Retatrutide phase 3 readouts and potential filing — could re-rate the obesity franchise.
- · Quarterly tirzepatide revenue prints and updates on manufacturing capacity coming online (construction-in-progress conversion).
- · Verve-102 cardiovascular gene editing data progression following positive early signal.
- · FDA shortage status resolution for tirzepatide and outcome of compounding-related litigation.
- · Kisunla uptake metrics in early Alzheimer's, plus competing Leqembi dynamics.
- · Any IRA negotiation outcomes or U.S. government pricing actions affecting GLP-1 class.
Key risks
- · Manufacturing/supply execution failure on tirzepatide capacity expansion.
- · Accelerated competitive erosion from oral GLP-1s (including Lilly's own orforglipron, paradoxically) and lower-cost global entrants.
- · Multiple compression if growth decelerates — at 38x P/E, a re-rating to 25x on slower growth implies material downside even with EPS growth.
- · Regulatory/pricing action on obesity drugs (IRA, Medicare/Medicaid coverage decisions).
- · M&A integration failures across the recent acquisition spree producing impairment charges.
Price target rationale
Applies ~35x forward P/E to estimated ~$33.5 2026 EPS (assuming ~20% EPS growth off $28.12 trailing), reflecting premium-but-disciplined multiple for a mid-30s% growth biopharma. This sits below the $1,211 street mean given valuation/competition risks but well above the $850 low, implying ~10% upside over 12 months.
On Wall Street's view (mixed): We broadly agree with the buy consensus given the depth of the GLP-1 franchise and retatrutide optionality, but the $1,211 mean target embeds continued multiple support that we view as fragile; our target sits modestly below the street's mean.
Latest filing (10-K)
Eli Lilly is essentially a tirzepatide (Mounjaro/Zepbound) story: the GIP/GLP-1 drug is driving ~32% revenue growth to ~$45B in 2025, and the entire investment thesis hinges on whether supply can be built fast enough and payer access broadened before competitors close the gap.
Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures, and markets human pharmaceutical products across cardiometabolic health, oncology, immunology, and neuroscience. The company generates revenue primarily through product sales in approximately 90 countries, with the U.S. as its largest market, supplemented by collaboration and licensing revenue. Lilly's growth is overwhelmingly driven by its GLP-1/GIP receptor agonist franchise, particularly tirzepatide (Mounjaro for diabetes, Zepbound for obesity), which has become the company's dominant revenue engine.
What the news says · bullish
The dominant storyline for LLY centers on strong clinical momentum, particularly promising retatrutide data showing bariatric-level weight loss results and positive Verve-102 heart study outcomes, which have driven a notable share price surge in late May 2026. GLP-1 drug expansion narratives continue to underpin the long-term bull case, with multiple outlets framing LLY as a top growth stock. However, some coverage raises valuation concerns — asking whether it is 'too late' to buy after a 7x five-year surge and a recent share price jump — and earlier April headlines flagged a stock 'flop' and downside risk near earnings, suggesting the stock is not without volatility and skepticism. Overall, the weight of recent news leans constructively bullish, driven by pipeline catalysts, though stretched valuation remains a legitimate counterpoint.
This analysis is from May 26, 2026. Markets move. Get the current read on LLY and generate fresh AI research on any ticker.
Every call we make is tracked publicly against what the stock actually did. See the track record →
One free AI report every day. No card required.